TCGA-AR-A2LK-01A-11R-A180-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 55
- os_event
- true
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.560
- G2M_CHECKPOINT+0.510
- MITOTIC_SPINDLE+0.430
- MYC_TARGETS_V1+0.300
- PROTEIN_SECRETION+0.280
- DNA_REPAIR+0.250
- UNFOLDED_PROTEIN_RESPONSE+0.250
- UV_RESPONSE_DN+0.220
- MYC_TARGETS_V2+0.210
- ESTROGEN_RESPONSE_EARLY+0.190
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.510
- TNFA_SIGNALING_VIA_NFKB-0.390
- HEDGEHOG_SIGNALING-0.370
- ALLOGRAFT_REJECTION-0.360
- KRAS_SIGNALING_DN-0.330
- APICAL_JUNCTION-0.260
- HYPOXIA-0.260
- CHOLESTEROL_HOMEOSTASIS-0.240
- IL6_JAK_STAT3_SIGNALING-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3307 | Med | Medulloblastoma | 0.877 |
| 2 | TCGA-E2-A15T-01A-11R-A115-07 | — | B | 0.866 |
| 3 | TCGA-E9-A1RE-01A-11R-A157-07 | — | B | 0.864 |
| 4 | TCGA-A8-A095-01A-11R-A00Z-07 | — | B | 0.860 |
| 5 | TCGA-A8-A0AB-01A-11R-A034-07 | — | B | 0.859 |
| 6 | TCGA-69-7973-01A-11R-2187-07 | — | cohortA3 | 0.852 |
| 7 | MBCProject_6109_T1B_RNA | — | B | 0.841 |
| 8 | MDT-AP-0167 | Med | Medulloblastoma | 0.839 |
| 9 | MNG1178 | — | — | 0.838 |
| 10 | MDT-AP-2497 | Med | Medulloblastoma | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.510 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.250 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.210 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.080 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.010 | Remibrutinib | — uncovered |